Skip to main content

Table 3 Rankings based on simulations

From: The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis

Endpoints

Ranks

DC

MDC

MDCI

Overall survival (HR (95% CrI))

Rank 1

0.07

0.20

0.73

Rank 2

0.21

0.67

0.13

Rank 3

0.72

0.13

0.14

Progression-free survival (HR (95% CrI))

Rank 1

0.18

0.30

0.52

Rank 2

0.23

0.53

0.24

Rank 3

0.59

0.17

0.24

Total severe events (OR (95% CrI))

Rank 1

0.75

0.11

0.14

Rank 2

0.20

0.68

0.12

Rank 3

0.05

0.21

0.74

Leukopenia (OR (95% CrI))

Rank 1

0.69

0.12

0.18

Rank 2

0.21

0.69

0.10

Rank 3

0.10

0.18

0.72

Thrombocytopenia (OR (95% CrI))

Rank 1

0.72

0.14

0.14

Rank 2

0.20

0.73

0.07

Rank 3

0.07

0.13

0.79

RBC transfusion (OR (95% CrI))

Rank 1

0.55

0.31

0.14

Rank 2

0.30

0.43

0.27

Rank 3

0.15

0.25

0.60

PLT transfusion (OR (95% CrI))

Rank 1

0.63

0.20

0.17

Rank 2

0.19

0.58

0.22

Rank 3

0.19

0.21

0.59

G-CSF (OR (95% CrI))

Rank 1

0.71

0.12

0.17

Rank 2

0.22

0.67

0.11

Rank 3

0.07

0.20

0.73

Hospitalization (OR (95% CrI))

Rank 1

0.74

0.10

0.16

Rank 2

0.21

0.69

0.10

Rank 3

0.05

0.21

0.74

  1. HR hazard ratio, OR odds ratio, 95% CrI 95% credible intervals, RBC red blood cell, PLT platelet, G-CSF granulocyte colony-stimulating factor, DC doxorubicin + cisplatin, MDC methotrexate + doxorubicin + cisplatin, MDCI methotrexate + doxorubicin + cisplatin + ifosfamide